Shots:

• Promedior to receive $390M up front and up to $1B development- regulatory and commercial milestones- making the total deal value as $1.39B. Roche to get full rights for Promedior's fibrotic diseases portfolio including its lead asset PRM-151
• The acquisition will leverage Roche’s drug development capabilities and expertise to further advance PRM-151 in fibrotic diseases- including idiopathic pulmonary fibrosis and myelofibrosis
• Promedior’s PRM-151 is a recombinant form of human pentraxin-2 (PTX-2) protein- demonstrated both prevention and reversal of fibrosis and has received FDA’s breakthrough therapy designation for IPF in H1’19

Click here to­ read full press release/ article 

 Ref: PRNewswire | Image: Roche